Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
-
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
-
Petrus Announces Results of Annual General Meeting of Shareholders
-
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
-
Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
-
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annu
-
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Lyme Timber Receives the 2025 SFI Leadership in Conservation Award for Advancing Nature-Based Solutions in SFI-Certified Forests
-
Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results
-
Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting
-
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
-
Taiho Oncology Presents Data at the 2025 American Society of Clinical Oncology Annual Meeting
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages BigBear.ai Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBAI
-
Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025
-
West Fraser Releases 2024 Sustainability Report
-
Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers
-
Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO® Annual Meeting
-
Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery
-
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal A
-
D. Boral Capital acted as Exclusive Placement Agent to Luminar Technologies (NASDAQ:LAZR) in connection with its up to $200.0 Million Equity Linked Securities Offering
-
Cerrado Gold Announces First Quarter Financial Results Release Date and Conference Call
-
ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis
-
City of Hope Researchers to Present Cancer Advances That Could Boost Survival at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
-
Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer
-
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
-
Ontario International Airport passenger count up for 50th consecutive month in April
-
Novita Highlights Positive Data from Phase 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors at 2025 ASCO Annual Meeting
-
Clear Blue Technologies International to provide Corporate Update and Report Q1 2025 Financial Results and Host Conference Call on Thursday, May 29th, 2025
-
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
-
Foresight Diagnostics Presents Independent Validation of its CLARITY Minimal Residual Disease (MRD) Assay in Multicenter Study of Frontline DLBCL at the 2025 ASCO Annual Meeting
-
Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting
-
Flatiron Health Announces Research to Be Presented at ASCO 2025
-
THOR Industries Announces Date for its Fiscal 2025 Third Quarter Earnings Release
-
ASCO Study Abstract Shows Cizzle Bio's CIZ1B Biomarker Test for Lung Cancer Could Save $518M in Annual Medicare Costs
-
Northisle Announces Board Slate for 2025 AGM
-
MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 that Highlights the Role of MicroRNA-based Genetic Signatures in Predicting Radiation and
-
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
-
COOFANDY Marks 10th Anniversary with Dual Silver Awards at Berlin and New York Product Design Competitions
-
VCI Global Revises Equity Agreement with 102% Premium Pricing, Enhancing Strategic Flexibility
-
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
-
Everyday People Financial to Present at Centurion One Capital 6th Annual LA Summit
-
Wheaton Precious Metals Publishes 2024 Sustainability Report and 2024 Climate Change Report
-
Liquid Networx Wins Fortinet’s Unified SASE Partner of the Year Award
-
Cal Redwood Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
-
Maryna Karpenko Wins Top Industry Honors for Shaping Global Communication
-
Lynch Carpenter Investigates Claims in Harbin Clinic Data Breach
-
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
-
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
-
Cosmic Wire and Sovereign Wealth Management Reshape the Future of Blockchain Infrastructure and the Spatial Web
